Literature DB >> 31284767

Asparaginase immune complexes induce Fc-γRIII-dependent hypersensitivity in naive mice.

Sanjay Rathod1,2, Manda Ramsey1,2, Danielle DiGiorgio1,2, Roberto Berrios1,2, Fred D Finkelman3,4, Christian A Fernandez1,2.   

Abstract

Asparaginase (ASNase) is an important drug for the treatment of leukemias. However, hypersensitivity to ASNase can increase the risk of leukemia relapse. Two mechanisms of ASNase hypersensitivity have been identified in mice. The existence of a pathway involving anti-ASNase IgG and Fc-γ receptor III (Fc-γRIII) implies that IgG and ASNase immune complexes (ICs) could directly induce hypersensitivity. The aim of this study was to detect ASNase ICs in mice after hypersensitivity reactions and determine their role in hypersensitivity. Protein G beads were used to detect plasma ASNase ICs by flow cytometry. Anti-ASNase IgG was purified from the plasma of sensitized mice, and ASNase ICs were prepared ex vivo at various ratios of ASNase to anti-ASNase IgG. The levels of ASNase ICs detected after hypersensitivity reactions correlated with reaction severity (R2 = 0.796; P = 0.0005). ASNase ICs prepared ex vivo required high levels of anti-ASNase IgG for formation, and binding to naive and sensitized immune cells depended on soluble anti-ASNase IgG, antigen:antibody ratio, and Fc-γRIII. Similarly, basophil activation by ASNase ICs depended on the antigen:antibody ratio and Fc-γRIII. Consistent with the ex vivo results, naive mice receiving ASNase ICs developed hypersensitivity reactions. Our data demonstrate that ASNase ICs can directly contribute to the onset and severity of ASNase hypersensitivity.-Rathod, S., Ramsey, M., DiGiorgio, D., Berrios, R., Finkelman, F. D., Fernandez, C. A. Asparaginase immune complexes induce Fc-γRIII-dependent hypersensitivity in naive mice.

Entities:  

Keywords:  anaphylaxis; antidrug antibodies; basophil activation test; immunogenicity; leukemia

Mesh:

Substances:

Year:  2019        PMID: 31284767      PMCID: PMC6766650          DOI: 10.1096/fj.201900857

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  28 in total

1.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Authors:  C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling
Journal:  Leukemia       Date:  2012-04-09       Impact factor: 11.528

Review 2.  Fcgamma receptors as regulators of immune responses.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

3.  Toxicity of E. coli L-asparaginase in man.

Authors:  H F Oettgen; P A Stephenson; M K Schwartz; R D Leeper; L Tallai; C C Tan; B D Clarkson; R B Golbey; I H Krakoff; D A Karnofsky; M L Murphy; J H Burchenal
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

4.  Evaluation of the antigenicity of hydrolyzed cow's milk protein formulas using the mouse basophil activation test.

Authors:  Hiroshi Iwamoto; Takeshi Matsubara; Yuki Nakazato; Kazuyoshi Namba; Yasuhiro Takeda
Journal:  Toxicol Lett       Date:  2015-11-25       Impact factor: 4.372

5.  Pathways of anaphylaxis in the mouse.

Authors:  Richard T Strait; Suzanne C Morris; Mingyan Yang; Xiao-Wu Qu; Fred D Finkelman
Journal:  J Allergy Clin Immunol       Date:  2002-04       Impact factor: 10.793

6.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Authors:  Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Jane O'Brien; Suzanne E Dahlberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Marshall Schorin; Mary V Relling; Harvey J Cohen; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

7.  Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.

Authors:  M H Woo; L J Hak; M C Storm; W E Evans; J T Sandlund; G K Rivera; B Wang; C H Pui; M V Relling
Journal:  Leukemia       Date:  1998-10       Impact factor: 11.528

8.  High-throughput asparaginase activity assay in serum of children with leukemia.

Authors:  Christian A Fernandez; Xiangjun Cai; Allie Elozory; Chengcheng Liu; J Carl Panetta; Sima Jeha; Alejandro R Molinelli; Mary V Relling
Journal:  Int J Clin Exp Med       Date:  2013-08-01

Review 9.  Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.

Authors:  Barbara Asselin; Carmelo Rizzari
Journal:  Leuk Lymphoma       Date:  2015-03-11

10.  Decreased expression of CD200R3 on mouse basophils as a novel marker for IgG1-mediated anaphylaxis.

Authors:  Hiroshi Iwamoto; Takeshi Matsubara; Yuki Nakazato; Kazuyoshi Namba; Yasuhiro Takeda
Journal:  Immun Inflamm Dis       Date:  2015-06-16
View more
  2 in total

1.  Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia.

Authors:  Arcangelo Iannuzzi; Mario Annunziata; Giuliana Fortunato; Carola Giacobbe; Daniela Palma; Alessandro Bresciani; Emilio Aliberti; Gabriella Iannuzzo
Journal:  Front Genet       Date:  2022-02-14       Impact factor: 4.599

2.  Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice.

Authors:  Sanjay Rathod; Manda Ramsey; Fred D Finkelman; Christian A Fernandez
Journal:  Blood Adv       Date:  2020-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.